Capitalizing on cellular ‘housekeeping’ could help beat age-related diseases

brown mouse
Mice engineered to have high levels of autophagy are protected from age-related diseases like Alzheimer's. (Alexandra/München)

Scientists at UT Southwestern Medical School have spent the last two decades studying autophagy, the process cells use to throw out toxic substances that endanger their health. They discovered autophagy not only helps the body fight off infections, but it also protects against many age-related diseases such as cancer and neurological disorders.

The findings raised a question: Could boosting natural levels of autophagy be a safe way to improve health and extend life? A new study in mice, published in the journal Nature, suggests it might.

To answer the question, the researchers genetically engineered mice to have a mutation in a protein called beclin 1. The UT Southwestern team had previously discovered that the gene that makes this protein drives autophagy, and that mutating it prevents it from binding to an autophagy-inhibiting protein called Bcl-2. The mutation resulted in mice born with persistently high levels of autophagy.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The result: The animals lived 10% longer than normal mice and were less likely to develop heart disease, kidney problems and age-related cancer, according to a statement from the university.

RELATED: Scientists reveal secrets of ‘anti-aging’ hormones

The research builds on previous studies showing the genetically engineered mice seem to be protected against the natural decline in autophagy that occurs with age. A year ago, the UT Southwestern team reported that the engineered mice were less likely to develop Alzheimer’s disease.

In the new study, the scientists observed that mice with increased levels of autophagy are protected from the loss of klotho—a hormone that has been proven to regulate metabolism and longevity. Klotho is the target of several research programs aimed at combating diseases of aging, and it inspired the startup Klogene, which is working on new approaches to treating Alzheimer’s.

The next step for the UT Southwestern scientists is to develop drugs that disrupt the ability of beclin 1 to bind to Bcl-2, thereby increasing autophagy.

"These studies have important implications for human health and for the development of drugs to improve it," said Beth Levine, M.D., director of the Center for Autophagy Research at UT Southwestern, in the statement. "They show that strategies to increase the cellular housekeeping pathway of autophagy may retard aging and aging-related diseases.”

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.